FMP
Jan 14, 2026
On January 14, 2026, Goldman Sachs reiterated its "Buy" rating for CoStar Group (NASDAQ: CSGP), with the stock trading at $61.82. CoStar Group is a prominent global provider of online real estate marketplaces, information, and analytics. The company operates platforms like Apartments.com, which is a leading online marketplace for apartment listings.
CoStar Group reported a 5% increase in U.S. office leasing activity in 2025 compared to the previous year. This growth is significant as it marks a recovery from 2024, which had the lowest leasing volume in 15 years, excluding 2020. Boston emerged as the top growth market, with office tenants signing leases for approximately 410 million square feet of space throughout the year.
Apartments.com, under CoStar Group, released a report highlighting a growth in U.S. apartment rents. The national average rent rose to $1,708 in December 2025, a 0.1% increase from November. This increase is notable as it signifies a shift from the previous five months, which experienced flat or negative changes in monthly rent.
CoStar Group announced a $1.5 billion share repurchase program for 2026, following a $500 million buyback in 2025. The company projects its 2026 revenue to be between $3.78 billion and $3.82 billion, representing an approximate 18% growth over the midpoint of its 2025 guidance. CoStar anticipates a net income ranging from $175 million to $215 million and adjusted EPS between $1.22 and $1.33.
The stock for CSGP is currently priced at $61.82, reflecting an increase of 4.25% or $2.52. During the day, the stock fluctuated between a low of $58.14 and a high of $62.52. Over the past year, the stock reached a high of $97.43 and a low of $57.01. CSGP has a market capitalization of approximately $26.2 billion, with a trading volume of 12,644,684 shares on the NASDAQ exchange.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapies f...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapies f...